Our principal, Ms. Pauli Wong, was invited to speak at the Hong Kong Life Sciences Society (HKLSS) Summer Internship Program 2024 on “Unlocking Patent Law: Exploring IP Career Paths” in July. This program aims to cultivate young talents to drive life sciences innovation. In addition, she participated in the discussion session titled “Evolving Landscape – Investment Outlook for the Healthcare and Life Sciences Sectors” alongside Mr. Tian Tan, the Vice President of NF Trinity.

Pauli shared her career journey becoming a patent attorney at Eagle IP, from an HKU biotech graduate and a scientist with CK Life Sciences. She provided an introduction to intellectual property, particularly patents, and life sciences challenges we are facing, and how to pursue a career path in patent law. By sharing her own experiences, Pauli offered valuable insights and guidance to the aspiring interns to appreciate the importance of IP and consider a career path in patent law.

我們過去活動

Recommended Insights

The Secret Prior Art Trap: A Case Study on Conflicting Applications in China

2025年11月13日
In patent prosecution, the concept of a "conflicting application" or “secret prior art” plays a critical role in determining the patentability of an invention. This article explores the framework for assessing conflicting applications under Chinese patent law, with a comparative perspective on the approaches adopted in the United States. Case Background: The Image Encoding Dispute […]

When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents

2025年9月30日
Starting in 2023, Datang Mobile, one of the key players in China’s telecom standardization efforts, initiated infringement proceedings against Samsung in China, Germany, and the US. Samsung responded by filing multiple invalidation petitions in several jurisdictions, including China, the United States, and Europe. The case discussed below is one of above-mentioned invalidation cases in China, […]

Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data

2026年1月23日
On December 31, 2025, The Supreme People's Court upheld the Beijing IP Court's decision, meaning that the semaglutide patent remains valid and will expire on March 20, 2026. Novo Nordisk announced this positive news via a press release on the day the case was decided. The Chinese Ministry of Commerce has also confirmed this decision […]

A More Detailed Overview of China’s Patent Term Extension (PTE) System

2024年6月17日
Although PTE has been in the Chinese Patent Law since the 4th Amendment of the law came into effect June 1, 2021, we didn’t really know the exact details of how it operated until the Implementation Regulations and Examination Guidelines (“Implementation Regulations”) were finally released in December 2023. New Rules 77-84 in the Implementation Regulations […]
Top crossarrow-right